
Topic
Oncology
HER2-targeted therapy, tumor-type access, buy-and-bill reimbursement, oncology biosimilars, and cancer drug coverage.

Pipeline· July 22, 2026 · 17 min read
By Ran Chen#ADC#Oncology#Clinical Trials

Pipeline· July 22, 2026 · 17 min read
Radioligand Therapy Clinical Trials by the Numbers (2026)
By Ran Chen#Oncology#Clinical Trials#Specialty Drugs

Deals· July 20, 2026 · 17 min read
2026 biopharma M&A by the numbers: 33 deals and $134 billion already eclipse all of 2025
By Ran Chen#M&A#Oncology#Immunology

Pricing & Access· July 18, 2026 · 18 min read
Sarclisa Escena SC access: CirCLIQ on-body injector, trial data, and billing
By Ran Chen#Oncology#FDA Approval#Specialty Pharmacy

Approvals· July 16, 2026 · 19 min read
Revtorpyk (gedatolisib) coverage: breast cancer approval and billing
By Ran Chen#Oncology#Breast Cancer#FDA Approval

Pricing & Access· July 11, 2026 · 16 min read
GSK Portfolio Dossier: ViiV HIV, Nucala Runway, and Oncology Rebuild
By Ran Chen#HIV#Respiratory#Infectious Disease

Pricing & Access· July 10, 2026 · 21 min read
AstraZeneca Portfolio Dossier: Farxiga Cliff, Enhertu Pivot, and Soliris Conversion
By Ran Chen#Orange Book#Purple Book#Medicare Part D

Pricing & Access· July 7, 2026 · 17 min read
BMS Portfolio Dossier: The Eliquis Cliff, Opdivo Lifecycle, and Cobenfy Bet
By Ran Chen#Orange Book#Purple Book#Medicare Part D

Specialty· July 7, 2026 · 21 min read
Voranigo (vorasidenib) Glioma Access: Pricing, Biomarker Testing, and Payer PA
By Ran Chen#Oncology#Orphan Drug#Prior Authorization

Pricing & Access· July 6, 2026 · 16 min read
Merck Portfolio Dossier: Keytruda QLEX, the Januvia Cliff, and a Post-2028 Pipeline
By Ran Chen#Purple Book#Orange Book#Biosimilars